The role of @entity4672 (Femara(R)) in XXXX therapy: A clinical review.

@entity1 @entity137 @entity4672 @entity0 @entity440 @entity5
@entity4672 is a third-generation aromatase inhibitor for use in postmenopausal @entity1 with @entity0 . This drug was found to reduce or effectively shrink @entity5 in a significant number of such @entity1 . It exhibits antitumor activity at a relatively low daily dose, and is highly potent and selective and well tolerated. Results from recent phase III clinical studies have confirmed the efficacy and the key role of this drug in the therapy of @entity0 in postmenopausal @entity1 . Moreover, @entity4672 demonstrated higher activity and lower @entity137 compared to @entity440 in the first-line therapy of postmenopausal @entity1 affected with @entity0 . However, it also represents a valid option in second-line therapy after @entity440 failure. New data on this agent in adjuvant or neoadjuvant treatment also suggest efficacy in the treatment of early @entity0 . This article reviews the clinical data on @entity4672 in all settings and its future potential in chemoprevention. (c) 2001 Prous Science. All rights reserved.
